{"id":"NCT02611687","sponsor":"Bioprojet","briefTitle":"Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period","officialTitle":"Double Blind, Multicentre, Randomized, Placebo-controlled Trial to Evaluate Safety and Efficacy of Pitolisant in Children From 6 to Less Than 18 Years With Narcolepsy With/Without Cataplexy, Followed by a Prolonged Open-label Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06-06","primaryCompletion":"2021-04-03","completion":"2025-06-05","firstPosted":"2015-11-23","resultsPosted":"2024-09-19","lastUpdate":"2025-06-26"},"enrollment":110,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Narcolepsy With Cataplexy","Narcolepsy Without Cataplexy"],"interventions":[{"type":"DRUG","name":"pitolisant","otherNames":["BF2.649"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"pitolisant","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this multicenter double blind study is to assess efficacy and safety of Pitolisant versus placebo in paediatric Narcoleptic patients with or without cataplexy.","primaryOutcome":{"measure":"To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score.","timeFrame":"8 weeks","effectByArm":[{"arm":"Pitolisant","deltaMin":-6.29,"sd":1.14},{"arm":"Placebo","deltaMin":-2.6,"sd":1.35}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":11,"countries":["Finland","France","Italy","Netherlands","Russia"]},"refs":{"pmids":["36931805"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":73},"commonTop":["Headache","Insomnia","Influenza","Upper respiratory tract infection","Diarrhoea"]}}